NCT05152147 2026-04-17
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
Clinical Trials
56 trialsNCT04389632 2026-04-07
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT06657144 2026-04-06
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Recruiting
NCT05489211 2026-03-19
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04882241 2026-03-06
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT03675737 2026-02-27
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT03615326 2025-12-11
MK-3475-811
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT03469557 2024-10-23
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
BeiGene
Phase 2 Completed
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT01285557 2024-09-19
DIGEST
Taiho Oncology, Inc.
Phase 3 Terminated
NCT00072787 2024-09-03
Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer
Taiho Oncology, Inc.
Phase 1/2 Completed
NCT03382600 2024-06-11
KEYNOTE-659
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01047007 2023-09-21
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02494583 2023-04-13
MK-3475-062
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated
NCT02335411 2022-08-08
KEYNOTE-059
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05173142 2022-03-08
HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors
Hutchmed
Phase 1/2 Unknown
NCT04859582 2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT01774786 2020-12-30
JACOB
Hoffmann-La Roche
Phase 3 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT01040312 2019-05-23
An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
Daiichi Sankyo
Completed
NCT00215644 2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT01461057 2018-08-09
JOSHUA
Hoffmann-La Roche
Phase 2 Completed
NCT02359058 2018-01-24
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00887822 2017-03-01
AVATAR
Hoffmann-La Roche
Phase 3 Completed
NCT01450696 2016-11-28
HELOISE
Hoffmann-La Roche
Phase 3 Terminated
NCT02563054 2016-11-02
A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00454636 2016-09-29
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT02137343 2016-04-04
RILOMET-2
Amgen
Phase 3 Terminated
NCT01697072 2016-02-09
RILOMET-1
Amgen
Phase 3 Terminated
NCT00553696 2015-03-13
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
Pfizer
Phase 1 Completed
NCT01041404 2014-11-05
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00343239 2014-11-04
NEOTAX
Sanofi
Phase 2 Completed
NCT00678535 2014-07-21
EXPAND
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT00583674 2014-05-07
Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
Amgen
Phase 2 Completed
NCT00719550 2013-12-05
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Amgen
Phase 1/2 Completed
NCT00842244 2013-11-27
Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
Phase 1 Completed
NCT01388790 2013-11-20
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00909402 2013-06-21
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
Bristol-Myers Squibb
Phase 1 Completed
NCT00555620 2013-01-14
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
Phase 1 Completed
NCT00811447 2012-08-31
Taxotere New Indication - Gastric Cancer Treatment Registration Trial
Sanofi
Phase 3 Completed
NCT01348009 2012-03-13
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
Genta Incorporated
Phase 1/2 Unknown